AxsomeAXSM
NASDAQPharmaceuticals
No cached AI snapshot yet for AXSM.
Be the first to run a multi-agent analysis on this ticker.
Key Stats
925 employees51.15M shares outstandinglisted 2015-11-19
Next earnings ~May 5, 2026
About Axsome
Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products include AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.
Latest News
Showing market-wide stock news
Axsome Therapeutics, Inc. (AXSM) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Treasury ETF shorts shift toward belly ahead of Fed decision
BoE to 'stand ready to hike', committee remains 'deeply divided'
The Fed’s interest rate decision in the epicenter of attention
News Flash: 70% of Wall Street Institutions Are Calling for at Least a 50-Basis-Point Fed Rate Hike in 2026
Nifty holds above 23,250 level; European shares trade mostly in green
Related Stocksin Pharmaceuticals
Ready to see the live AI view on AXSM?
Launch a real-time multi-agent room — Claude, GPT, Gemini, DeepSeek, Grok, and Qwen analyzing AXSM side-by-side with live signals.